Rethinking Hidradenitis suppurativa treatment: The shift towards metabolic therapies

The bottom line on Hidradenitis suppurativa treatment

Researchers have consolidated a systemic approach to Hidradenitis suppurativa treatment, targeting underlying hormonal and metabolic triggers instead of isolated skin lesions. The condition's multifactorial nature—driven by complex hormonal and immunometabolic interactions—requires scientists to aim directly at the engine of the disease: end-organ androgen hypersensitivity and systemic metabolic dysregulation.

Beyond surface-level symptoms

Because the disease is characterised by abnormal keratinocyte proliferation and follicular obstruction, managing it requires looking beyond the skin. The new review details how sex hormones and metabolic dysregulation actively contribute to the disease's pathogenesis, offering a proactive, endocrine-focused approach as a vital initial or adjunctive option.

The clinical data measured the high prevalence of comorbidities like type 2 diabetes, obesity, and polycystic ovary syndrome in afflicted patients. This consistent overlap suggests that the persistent skin lesions are intertwined with broader metabolic dysfunction. Consequently, managing the severity of the condition requires treating the metabolic components rather than just the dermis.

Targeting the metabolic engine

The investigators reviewed how specific hormonal and metabolic interventions can address the root causes of the disease. They outline how local androgen dysregulation and hypersensitivity actively contribute to the blocked hair follicles.

To counter this mechanism, the review outlines three primary therapeutic avenues:

• Systemic and topical hormonal therapies designed to address local androgen dysregulation.
• Metabolic interventions targeting underlying issues like insulin resistance and metabolic syndrome.
• Structured lifestyle modifications aimed at reducing adipokine-driven chronic inflammation.

The authors highlight that these targeted interventions serve as crucial components of multi-modal therapy. It is a rigorous, highly practical validation of treating the whole patient, though current data primarily validates these approaches within specific patient populations rather than as a universal cure.

What this analysis leaves unsolved

Despite the clarity this review provides regarding mechanisms and benefits, it exposes gaps in current clinical capabilities. Understanding which specific patient populations benefit most from these interventions remains essential, as the complex interactions mean that predicting individual responses requires careful clinical evaluation.

Furthermore, while the review details the clinical efficacy of these therapies, it acknowledges the inherent risks and limitations associated with manipulating systemic hormones and metabolic pathways.

Going forward, clinicians must balance these established endocrine strategies with the concurrent, robust development of new biologic drugs. The modern standard requires a highly organised, multi-modal approach to address both the dermatological symptoms and the underlying metabolic system.